Printer Friendly

Proton-pump inhibitors also effective in nonerosive reflux disease. (Accounts for 50%-70% of Gerd Cases).

SEATTLE--Proton-pump inhibitors, the therapeutic mainstay for gastroesophageal reflux disease, are also highly effective in the treatment of nonerosive reflux disease, according to a new metaanalysis.

That's good news, since nonerosive reflux disease (NERD) accounts for an estimated 50%-70% of total cases of gastroesophageal reflux disease (GERD). Prior to the metaanalysis, there wasn't really persuasive evidence that proton-pump inhibitors (PPIs) are effective in NERD. The great majority of data supporting PPI therapy in GERD come from clinical trials restricted to the minority of GERD patients having endoscopic evidence of erosive esophagitis, Dr. Ronnie Pass said at the annual meeting of the American College of Gastroenterology.

Indeed, after reviewing 107 studies on PPI therapy published or presented in abstract form since 1985, the investigators determined that only 6 randomized trials and 4 Food and Drug Administration reports met their criteria for inclusion in the metaanalysis, namely 4-week heartburn resolution data in patients with negative endoscopy or with endoscopic findings of erythema and friability but no erosions. The analysis included roughly 3,000 patients, said Dr. Pass of the University of Arizona, Tucson.

At 4 weeks, the rate of sufficient heartburn control--an end point defined as less than 1 day of moderate heartburn during the last 7 days of treatment--was 5 6.6% in PPI-treated patients and 22.9% in those randomized to placebo. For the more stringent end point of complete heartburn control, defined as no heartburn during the last 7 days of treatment, the rate was 36.6% with PPI therapy and 9.6% with placebo.
COPYRIGHT 2003 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Jancin, Bruce
Publication:OB GYN News
Date:Jul 1, 2003
Words:256
Previous Article:Chronic low-dose aspirin therapy tied to GI bleeding. (No Safe Dose?).
Next Article:Gastroesophageal reflux disease. (Women's Health Adviser).


Related Articles
The Long Arm of GERD.
Nighttime GERD Affects 79% of Adults With Heartburn.
Atypical GERD symptoms take time to tame. (Asthma, Laryngeal Polyps, Chronic Cough).
Nonerosive reflux disease responds well to PPIs. (Accounts for up to 70% of GERD Cases).
GERD surgery 'Excellent' for Select patients who fail medical therapy. (Rely on Objective Findings).
Diagnosing and treating GERD. (Clinical Capsules).
Food and Drug Administration clears permanent of acid reflux device.
Esophageal pH in GERD.
Weaning from PPIs easier in patients with milder reflux.
Medication confirmed as first choice for GERD.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters